Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended December 31, 2025
Business Overview: A clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral drugs using a host-mimicry nanomedicine platform. The company operates from a cGMP-compliant facility in Shelton, Connecticut, and has no commercial product revenue to date.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,005,777) | $(5,154,302) |
| Net Loss Per Share (Basic & Diluted) | $(0.22) | $(0.36) |
| Cash and Cash Equivalents (Ending) | $5,150,580 | $3,958,052 |
| Net Cash Used in Operating Activities | $(3,643,512) | $(4,785,808) |
| Total Current Liabilities | $1,195,925 | $1,306,519 |
| Accumulated Deficit | $(152,847,638) | $(144,529,197) |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $1.15 million (22%) for the six-month period compared to the prior year, driven primarily by a $977,727 decrease in Research and Development (R&D) expenses due to reduced outside lab fees and clinical trial costs.
- Capital Raising: The company significantly improved liquidity through equity financing. It raised approximately $5.4 million net in a Registered Direct Offering and Private Placement (PIPE) in November 2025, and approximately $1.9 million net via At-The-Market (ATM) sales during the six-month period.
- Balance Sheet Strength: Cash and cash equivalents increased from $1.56 million at June 30, 2025, to $5.15 million at December 31, 2025. Total stockholders' equity increased to $11.07 million.
- Expense Fluctuations: While R&D decreased, General and Administrative (G&A) expenses increased by $211,825 for the quarter ended December 31, 2025, attributed to higher professional fees for investor outreach.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Lead Drug Candidate (NV-387): The company is advancing NV-387, a broad-spectrum antiviral, into Phase II clinical trials. Key milestones include submitting the Phase Ia/Ib clinical study report to Indian regulators and initiating a Phase II trial for MPox treatment in the Democratic Republic of Congo (DRC).
- Orphan Drug Strategy: The company filed for Orphan Drug Designation (ODD) with the FDA for NV-387 to treat Measles, MPox, and Smallpox. Success could accelerate regulatory timelines and enable non-dilutive government funding.
- Manufacturing: The company continues to utilize its in-house cGMP facility to manufacture drug substances and products, aiming to reduce costs and expedite clinical supply.
Risks and Contingencies
- Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. Management believes current cash resources ($5.2 million) and a $3 million line of credit (undrawn) are insufficient to fund operations for the next 12 months.
- Financing Dependency: Continued operations depend on securing additional financing through equity, debt, or non-dilutive grants. There is no assurance that such funding will be available on acceptable terms.
- Related Party Transactions: Significant liabilities exist to related parties (TheraCour and KMPL), totaling approximately $929,000 in accounts payable. The company relies on exclusive licenses from TheraCour for its technology.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion given the "substantial doubt" disclosure and the lack of revenue.
- Financing Terms: Review the dilution impact of the recent Registered Direct Offering and the terms of the $3 million line of credit with the CEO.
- Clinical Milestones: Confirm the status of the Phase Ia/Ib study report submission and the regulatory approval status for the Phase II MPox trial in the DRC.
- Related Party Payables: Assess the repayment terms and potential conversion of the $929,000 owed to related parties (TheraCour and KMPL).
- Orphan Drug Status: Monitor the FDA's response to the Orphan Drug Designation applications for Measles, MPox, and Smallpox.